Company Overview
Snapshot
Founded in February 2021 by Gil Shklarski, Micha Breakstone, and Edmund Benami, NeuraLight operates with 11–50 employees. The company has raised $30.5 million across 2 funding rounds from 9 investors, with Koch Disruptive Technologies leading a significant Series A round in May 2022.
Business overview
NeuraLight is developing an AI-driven platform to enhance drug development, monitoring, and care for patients with neurological disorders. Its core technology leverages standard smartphones or webcams to automatically extract micro-oculometrics, generating objective and sensitive digital markers for neurological conditions. The platform aims to serve as a robust proxy for existing endpoints, establishing a new measurement standard for precision medicine in neurology. NeuraLight focuses on transforming patient evaluation and care for neurological disorders, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics.
Strategic signal
In April 2023, NeuraLight introduced a new assessment tool for ALS based on abnormal eye movements. This development signals the company's progress in translating its AI-driven platform into practical diagnostic tools, potentially accelerating the detection and monitoring of complex neurological diseases and validating its approach to digitizing neurology.
Log in to access full profile ›Company Intelligence Q&A
- What is NeuraLight's primary focus?
- NeuraLight is focused on building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders.
- When was NeuraLight founded and by whom?
- NeuraLight was founded in February 2021 by Gil Shklarski, Micha Breakstone, and Edmund Benami.
- What was NeuraLight's most recent funding round?
- In May 2022, NeuraLight secured Series A funding, led by Koch Disruptive Technologies.
- What technology does NeuraLight utilize?
- NeuraLight's platform automatically extracts micro-oculometrics using information captured with a standard smartphone or webcam, leveraging AI and computer vision for digital markers of neurological disorders.
- What was a significant product development for NeuraLight in 2023?
- In April 2023, NeuraLight developed a new assessment tool for ALS based on abnormal eye movements, aiming to provide more precise neurological diagnostics.